Transaction Overview
On November 10, 2026, Steven Glassman, a director of NEXGEL, INC. (NASDAQ:NXGL), purchased 4,546 shares of the company’s common stock at $5.50 per share, resulting in a total outlay of $25,003. At the time of the purchase the market price was $3.88 per share, indicating a discount to the transaction price. The acquisition was executed through a private placement in which each unit comprised one share of common stock and one PIPE warrant; the warrant carries an exercise price of $10.00 per share and expires on November 10, 2031, with no separate consideration paid for the warrant.
Derivative Security Adjustments
On the same date, Glassman amended two existing derivative securities. A Convertible Promissory Note originally convertible at $12.00 per share was revised to a conversion price of $5.50 per share. Additionally, an existing warrant’s exercise price was reduced from $16.00 to $13.00 per share. The filing notes that these amendments represent the disposition of the original securities and the acquisition of the amended versions for reporting purposes, while the original securities remain outstanding in their amended form.
Post‑Transaction Holding and Share Structure
Following the transactions, Glassman’s direct holding in NEXGEL common stock increased to 12,379 shares. All share counts reflect a 1‑for‑20 reverse stock split of NEXGEL’s common stock that became effective on October 12, 2026.
Stockholder Meeting and Authorized Share Increase
In a separate development, NEXGEL’s 2026 Special Meeting of Stockholders approved an amendment to the certificate of incorporation to increase the authorized common shares from 25,000,000 to up to 150,000,000. The amendment received 5,416,811 votes in favor, 779,208 votes against, and 4,024 abstentions. The meeting achieved quorum with 6,200,043 shares represented out of 9,747,663 shares entitled to vote. The board now has discretion to file the amendment within one year of the stockholder approval.
Additional Context
InvestingPro analysis cited in the source suggests that NEXGEL appears undervalued at current market levels, with a fair value estimate of $5.41 per share. The article was generated with AI assistance and reviewed by an editor.